Advertisement

Annals of Hematology

, Volume 98, Issue 3, pp 647–656 | Cite as

Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma

  • Jan A. StratmannEmail author
  • Aaron Becker von Rose
  • Sebastian Koschade
  • Knut Wendelin
  • Friedemann Köhler
  • Michael Heinsch
  • Kilian Schiller
  • Claudia Haferlach
  • Mohamed Wattad
  • Harald Rieder
  • Hubert Serve
  • Nicola Gökbuget
  • Björn Steffen
Original Article

Abstract

The 2016 revised World Health Organization (WHO) classification of lymphoid neoplasms included the category of high-grade B cell lymphomas (HGBLs) with combined MYC and BCL2 and/or BCL6 rearrangements (double-hit, DH). However, the clinical features of B cell precursor leukemia (BCP-ALL) that harbor DH genetics remain widely unknown. We performed a retrospective analysis of the German Multicenter Study Group for Adult ALL registry and a literature search for de novo DH-BCP-ALLs. We identified 6 patients in the GMALL registry and 11 patients published in the literature between 1983 and June 2018. Patients of all ages (range, 15–86 years) are affected. There is a high incidence of meningeal disease and other extramedullary disease manifestations. Current treatment approaches are mainly ALL-based and are sufficient to induce first complete remissions, but progression-free survival is only 4.0 months (95% CI, 1.5–6.5 months) and all patients succumb to their disease, once relapsed, with a median survival of 5.0 months (95% CI, 3.1–6.9 months), despite intensive salvage and targeted therapy approaches. Of all patients, only two that attained an initial complete remission were alive at data cutoff. In all cases, the BCL2 gene was rearranged to be in proximity to the IGH locus, whereas MYC had various translocation partners juxtaposed. There was no significant survival difference between IG and non-IG translocation partners (HR, 1.03; 95% CI, 0.33–3.2; p = 0.89). In conclusion, de novo DH-BCP-ALL is an aggressive B cell malignancy with deleterious outcome. Physicians have to be aware of this rare disease subset due to the atypical clinical behavior and especially because latest classification systems do not cover this sub-entity.

Keywords

Acute lymphoblastic B cell precursor leukemia MYC BCL2 Double-hit Extramedullary manifestation Salvage treatment 

Notes

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Disclosures of conflict of interest

Prof. Haferlach reports reimbursements for diagnostic services from the MLL Munich Leukemia Laboratory during the conduct of this study; and being a part owner of the MLL Munich Leukemia Laboratory; The other authors declare no conflicts of interest.

Supplementary material

277_2018_3590_MOESM1_ESM.docx (30 kb)
ESM 1 (DOCX 29 kb)
277_2018_3590_Fig2_ESM.png (166 kb)
ESM 2

(PNG 166 kb)

277_2018_3590_MOESM2_ESM.tif (1.3 mb)
High resolution image (TIF 1353 kb)
277_2018_3590_Fig3_ESM.png (395 kb)
ESM 3

(PNG 395 kb)

277_2018_3590_MOESM3_ESM.tif (3 mb)
High resolution image (TIF 3052 kb)

References

  1. 1.
    Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E, Jack A (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol Off J Am Soc Clin Oncol 28(20):3360–3365.  https://doi.org/10.1200/JCO.2009.26.3947 CrossRefGoogle Scholar
  2. 2.
    Niitsu N, Okamoto M, Miura I, Hirano M (2009) Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23(4):777–783.  https://doi.org/10.1038/leu.2008.344 CrossRefGoogle Scholar
  3. 3.
    Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond. Evolving concepts and practical applications. Blood 117(19):5019–5032.  https://doi.org/10.1182/blood-2011-01-293050 CrossRefGoogle Scholar
  4. 4.
    Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR (2014) Double hit lymphoma. The MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891–901.  https://doi.org/10.1111/bjh.12982 CrossRefGoogle Scholar
  5. 5.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390.  https://doi.org/10.1182/blood-2016-01-643569 CrossRefGoogle Scholar
  6. 6.
    Miyaoka M, Kikuti YY, Carreras J, Ikoma H, Hiraiwa S, Ichiki A, Kojima M, Ando K, Yokose T, Sakai R, Hoshikawa M, Tomita N, Miura I, Takata K, Yoshino T, Takizawa J, Bea S, Campo E, Nakamura N (2018) Clinicopathological and genomic analysis of double-hit follicular lymphoma. Comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Mod Pathol 31(2):313–326.  https://doi.org/10.1038/modpathol.2017.134 CrossRefGoogle Scholar
  7. 7.
    Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Facchetti F, Pileri S, Rosenwald A, Wotherspoon A, Fend F (2017) The clinicopathologic spectrum of mature aggressive B cell lymphomas. Virchows Arch 471(4):453–466.  https://doi.org/10.1007/s00428-017-2199-7 CrossRefGoogle Scholar
  8. 8.
    Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, Haferlach C (2014) TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood 124(2):251–258.  https://doi.org/10.1182/blood-2014-02-558833 CrossRefGoogle Scholar
  9. 9.
    Motlló C, Ribera J-M, Morgades M, Granada I, Montesinos P, González-Campos J, Fernández-Abellán P, Tormo M, Bethencourt C, Brunet S, Hernández-Rivas JM, Moreno MJ, Sarrà J, del Potro E, Barba P, Bernal T, Grande C, Grau J, Cervera J, Feliu E, PETHEMA Group, Spanish Society of Hematology (2014) Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer 120(24):3958–3964.  https://doi.org/10.1002/cncr.28950 CrossRefGoogle Scholar
  10. 10.
    Harrison CJ, Martineau M, Secker-Walker LM (2001) The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia. A valuable resource for patient management. Br J Haematol 113(1):3–10CrossRefGoogle Scholar
  11. 11.
    Harrison CJ (2009) Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 144(2):147–156.  https://doi.org/10.1111/j.1365-2141.2008.07417.x CrossRefGoogle Scholar
  12. 12.
    Lafage-Pochitaloff M, Baranger L, Hunault M et al (2017) Value of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood.  https://doi.org/10.1182/blood-2017-05-783852
  13. 13.
    Liu W, Hu S, Konopleva M, Khoury JD, Kalhor N, Tang G, Bueso-Ramos CE, Jorgensen JL, Lin P, Medeiros LJ, Lu X (2015) De novo MYC and BCL2 double-hit B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in pediatric and young adult patients associated with poor prognosis. Pediatr Hematol Oncol 32:1–13.  https://doi.org/10.3109/08880018.2015.1087611 CrossRefGoogle Scholar
  14. 14.
    Marosi C, Bettelheim P, Chott A et al. (1992) Simultaneous occurrence of t(14;18) and t(8;22) common acute lymphoblastic leukemia. Ann Hematol 64(2):101–104Google Scholar
  15. 15.
    D'Achille P, Seymour JF, Campbell LJ (2006) Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genet Cytogenet 171(1):52–56.  https://doi.org/10.1016/j.cancergencyto.2006.07.005
  16. 16.
    Subramaniyam S, Fraser CR, Rao PH et al. (2011) De novo B lymphoblastic leukemia/lymphoma in an adult with t(14;18)(q32;q21) and c-MYC gene rearrangement involving 10p13. Leuk Lymphoma 52(11):2195–2199.  https://doi.org/10.3109/10428194.2011.589548
  17. 17.
    Nacheva E, Dyer MJ, Fischer P et al. (1993) C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353). Blood 82(1):231–240Google Scholar
  18. 18.
    Mufti GJ, Hamblin TJ, Oscier DG et al. (1983) Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. Blood 62(5):1142–1146Google Scholar
  19. 19.
    Uemura S, Hasegawa D, Yokoi T, Nino N, Tahara T, Tamura A, Saito A, Kozaki A, Kishimoto K, Ishida T, Kawasaki K, Yamamoto N, Mori T, Nishimura N, Kosaka Y (2017) Refractory double-hit lymphoma/leukemia in childhood mimicking B-precursor acute lymphoblastic leukemia at initial presentation. Rinsho ketsueki 58(2):143–149.  https://doi.org/10.11406/rinketsu.58.143 Google Scholar
  20. 20.
    Pegoraro L, Palumbo A, Erikson J et al. (1984) A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci USA 81(22):7166–7170Google Scholar
  21. 21.
    Gökbuget N, Kneba M, Raff T et al (2012) Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120(9):1868–1876.  https://doi.org/10.1182/blood-2011-09-377713 CrossRefGoogle Scholar
  22. 22.
    Hoelzer D, Walewski J, Dohner H, Viardot A, Hiddemann W, Spiekermann K, Serve H, Duhrsen U, Huttmann A, Thiel E, Dengler J, Kneba M, Schaich M, Schmidt-Wolf IGH, Beck J, Hertenstein B, Reichle A, Domanska-Czyz K, Fietkau R, Horst HA, Rieder H, Schwartz S, Burmeister T, Gokbuget N, for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (2014) Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy. Report of a large prospective multicenter trial. Blood 124(26):3870–3879.  https://doi.org/10.1182/blood-2014-03-563627 CrossRefGoogle Scholar
  23. 23.
    Snuderl M, Kolman OK, Chen Y-B, Hsu JJ, Ackerman AM, Cin PD, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34(3):327–340.  https://doi.org/10.1097/PAS.0b013e3181cd3aeb CrossRefGoogle Scholar
  24. 24.
    Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun H, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS (2014) Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma. A multicenter retrospective analysis. Blood 124(15):2354–2361.  https://doi.org/10.1182/blood-2014-05-578963 CrossRefGoogle Scholar
  25. 25.
    Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ (2012) B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25(1):145–156.  https://doi.org/10.1038/modpathol.2011.147 CrossRefGoogle Scholar
  26. 26.
    Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD (2017) Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol Off J Am Soc Clin Oncol 35(20):2260–2267.  https://doi.org/10.1200/JCO.2017.72.2157 CrossRefGoogle Scholar
  27. 27.
    Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D, on behalf of the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120(10):2032–2041.  https://doi.org/10.1182/blood-2011-12-399287 CrossRefGoogle Scholar
  28. 28.
    Pillai RK, Sathanoori M, van Oss SB, Swerdlow SH (2013) Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol 37(3):323–332.  https://doi.org/10.1097/PAS.0b013e31826cebad CrossRefGoogle Scholar
  29. 29.
    Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH, Medical Research Council of the United Kingdom Adult ALL Working Party and the Eastern Cooperative Oncology Group (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109(3):944–950.  https://doi.org/10.1182/blood-2006-05-018192 CrossRefGoogle Scholar
  30. 30.
    Gökbuget N, Dombret H, Ribera J-M et al (2016) International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101(12):1524–1533.  https://doi.org/10.3324/haematol.2016.144311 CrossRefGoogle Scholar
  31. 31.
    McPhail ED, Maurer MJ, Macon WR et al (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899–1907.  https://doi.org/10.3324/haematol.2018.190157 CrossRefGoogle Scholar
  32. 32.
    Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P (2017) Relapsed or refractory double-Expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol 35(1):24–31.  https://doi.org/10.1200/JCO.2016.68.2740 CrossRefGoogle Scholar
  33. 33.
    Chen AI, Leonard JT, Okada CY, Gay ND, Chansky K, Fan G, Dunlap JB, Raess PW, Braziel RM, Stentz A, Maziarz RT (2017) Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma. Leuk Lymphoma 59:1–6.  https://doi.org/10.1080/10428194.2017.1406085 Google Scholar
  34. 34.
    Pedersen MO, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Klausen TW, Nørgaard P (2014) MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol 92(1):42–48.  https://doi.org/10.1111/ejh.12212 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Jan A. Stratmann
    • 1
    Email author
  • Aaron Becker von Rose
    • 1
  • Sebastian Koschade
    • 1
  • Knut Wendelin
    • 2
  • Friedemann Köhler
    • 3
  • Michael Heinsch
    • 4
  • Kilian Schiller
    • 5
  • Claudia Haferlach
    • 6
  • Mohamed Wattad
    • 7
  • Harald Rieder
    • 8
  • Hubert Serve
    • 1
  • Nicola Gökbuget
    • 1
  • Björn Steffen
    • 1
  1. 1.Department of Hematology and OncologyJohann Wolfgang Goethe University of FrankfurtFrankfurt am MainGermany
  2. 2.Department of Hematology and Medical OncologyParacelsus Medical UniversityNurembergGermany
  3. 3.Department of. Internal Medicine IISchwarzwald-Baar Clinic Villingen-SchwenningenVillingen-SchwenningenGermany
  4. 4.Department of Internal Medicine IISt Johannes HospitalDuisburgGermany
  5. 5.Department of Radiation OncologyTechnical University of Munich (TUM)MunichGermany
  6. 6.Munich Leukemia Laboratory (MLL)MunichGermany
  7. 7.Department of Hematology and OncologyHospital Essen-WerdenEssenGermany
  8. 8.Institute for Human Genetics, Medical FacultyHeinrich-Heine-UniversityDüsseldorfGermany

Personalised recommendations